News | July 10, 2023
Novavax's Nuvaxovid receives full marketing authorization in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax’ clinical development program reported no severe allergic reactions
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The vaccine is under FDA review
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)